Anika Therapeutics Inc. is a medical device company focused on orthopedic hyaluronic acid (HA) technologies for osteoarthritis pain management and regenerative solutions. The company develops, manufactures, and commercializes HA-based products, including viscosupplements for joint pain and scaffolds for tissue repair. Its OA Pain Management portfolio includes Monovisc, Orthovisc, and Cingal, which are indicated for pain relief in osteoarthritis conditions. The Regenerative Solutions portfolio features the Integrity Implant System for rotator cuff and tendon repairs, Hyalofast for cartilage regeneration, and Tactoset for bone and tendon fixation. In the United States, Monovisc and Orthovisc are marketed exclusively by Johnson & Johnson MedTech, while Cingal is sold internationally through a network of distributors. The company also maintains a partnership with Boehringer Ingelheim Vetmedica for the distribution of Hyvisc, an equine osteoarthritis product. Anika Therapeutics was founded in 1992 as a spin-off of MedChem Products, Inc., and has divested its Arthrosurface and Parcus Medical subsidiaries to concentrate on its core HA-based business.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Medical Devices Homepage anika.com
Sector Healthcare IR page ir.anika.com
Tags
orthopedics, hyaluronic acid, osteoarthritis, viscosupplements, tissue engineering, tendon repair, cartilage regeneration, bone substitutes, pain management, regenerative medicine, Monovisc, Orthovisc, Cingal, Integrity, Hyalofast, Tactoset, Hyvisc, Amvisc, Amvisc Plus, Arthrosurface, Parcus Medical
Press page ir.anika.com/news-releases

Metrics

Valuation  
Market cap $ 263.326M
Market cap (USD) $ 263.326M
P/E -983.00
PEG —
P/BV 1.91
P/S 2.13
P/OCF 35.19
P/FCF 114.74
Dividend yield —
Turnover / mcap —
Returns  
ROE -7.3%
ROI -9.9%
ROIC -7.5%
Profit margin -9.6%
Growth  
Revenue growing No
Profits growing Yes
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding No
Buying back stock Yes
Diluting (TTM) No
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 16
Quality score -47.1%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006 FY 2005 FY 2004 FY 2003 FY 2002 FY 2001 FY 2000
Revenue 112.819M 119.907M 166.662M 156.236M 147.794M 130.457M 114.61M 105.555M 113.42M 103.379M 92.999M 105.595M 75.081M 71.359M 64.779M 55.557M 40.136M 35.78M 30.83M 26.841M 29.835M 26.466M 15.404M 13.187M 11.312M 16.335M
Net profit -10.88M -56.385M -82.667M -14.859M 4.134M -23.982M 27.193M 18.722M 31.816M 32.547M 30.758M 38.319M 20.575M 11.757M 8.467M 4.316M 3.688M 3.629M 6.035M 4.604M 5.893M 11.19M 827K -3.04M -6.758M 173.554K
Free cash flow 4.362M -2.331M -7.215M -3.077M 3.254M 11.437M 34.178M 30.262M 31.832M 9.787M 29.839M 38.425M 24.724M 9.044M 8.773M 5.068M -867.527K -12.839M -9.263M 695.371K 4.852M 23.35M 1.756M 243.118K -5.223M -2.389M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006 FY 2005 FY 2004 FY 2003 FY 2002 FY 2001 FY 2000
Share price 9.61 16.46 22.66 29.6 35.83 45.26 51.85 33.61 53.91 48.96 38.16 40.74 38.16 9.95 9.78 5.02 — 5.2 20.04 13.76 — — — — — —
Price performance 12m -0.42 -0.27 -0.23 -0.17 -0.21 -0.13 0.54 -0.38 0.1 0.28 -0.06 0.07 2.84 0.02 0.95 — — -0.74 0.46 — — — — — — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) 27.6M 23.8M 20.8M 23.1M 24.1M 29.8M 34.6M 36M 23.6M 23.7M
↳ YoY growth +27.5% -13.7% -12.8% +11.1% +4.4% +23.8% +16.0% +3.9% -34.4% +0.4%
↳ 5y CAGR +9.8% +2.1% +2.1% +6.1% +2.2% +1.6% +7.8% +11.6% +0.4% -0.3%
Borrowings, non-current (USD) — — — 0.00 — — — — — —
Lease liabilities (USD) — — — 21.4M 21.4M 19.2M 28.8M 26.9M 25.9M 26.2M
Cash and deposits (USD) 104M 133M 89M 157M 95.8M 94.4M 86.3M 72.9M 55.6M 57.5M
Intangible assets (USD) 10.2M 10.6M 9.19M 7.59M 91.2M 82.4M 74.6M 4.63M 2.49M 1.65M
Right-of-use assets (USD) — — — 22.9M 22.6M 21M 30.7M 28.8M 25.7M 25.9M
Net debt (borrowings + leases - cash) (USD) — — — -135M — — — — — —
Cash flow detail
Operating cash flow (USD) 23.8M 40.8M 34.9M 37M 13.1M 8.4M 4.41M -1.79M 5.4M 11.2M
Purchases of property, plant and equipment (USD) -14M -8.98M -4.66M -2.83M -1.63M -5.14M -7.49M -5.43M -7.73M -6.83M
Purchases of intangible assets (USD) — — — — — — 0.00 0.00 -600,000 0.00
Change in receivables (cash effect) (USD) -6.2M 2.67M 2.91M -1.84M 5.86M -6.22M -5.63M -1.31M 3.37M 408,000
Change in inventories (cash effect) (USD) -1.74M -6.52M -7.58M -5.59M -14.2M -6.62M -6.87M -11.4M -9.42M 30,000
Change in payables (cash effect) (USD) -5.06M 3.89M -1.67M 767,000 822,000 -1.1M 1.97M -11,000 -2.51M 42,000
Share buybacks (cash effect) (USD) -25M — -30M -30M 0.00 0.00 0.00 -5M -10.9M -9.49M
Income taxes paid (cash effect) (USD) -22.8M -15.1M -5.56M -9.26M -993,000 -1.23M -106,000 -3.12M -3.99M -1.08M
Share-based compensation (USD) 3.39M 5.81M 11M 6.09M 5.39M 11.1M 14.3M 15.2M 13.1M 10.1M
Operating cash flow before change in receivables (USD) 30M 38.1M 32M 38.8M 7.21M 14.6M 10M -483,000 2.04M 10.8M
Free cash flow (OCF - PPE - intangibles) (USD) 9.79M 31.8M 30.3M 34.2M 11.4M 3.25M -3.08M -7.22M -2.93M 4.36M
Income detail
Research and development expense (USD) 10.7M 18.8M 18.2M 16.7M 23.4M 27.3M 28.2M 32.7M 25.5M 25.8M
↳ 5y CAGR +11.7% +28.4% +20.8% +15.4% +21.1% +20.6% +8.4% +12.4% +8.9% +1.9%
Total comprehensive income (USD) 31.9M 34.3M 18M 26.8M -22.6M 2.96M -15.6M -82.2M -57.2M -9.06M
Comprehensive income to owners (USD) 31.9M 34.3M 18M 26.8M -22.6M 2.96M -15.6M -82.2M -57.2M -9.06M
Provision for credit losses (USD) 52,000 1.61M 57,000 -499,000 635,000 156,000 554,000 508,000 195,000 629,000
Credit cost ratio (credit losses / average receivables) (%) 0.2% 6.3% 0.3% 2.3% 2.7% 0.6% 1.7% 1.4% 0.7% 2.7%
Reported Feb 24, 2017 Feb 27, 2018 Feb 27, 2019 Aug 7, 2020 Mar 5, 2021 Mar 11, 2022 Mar 17, 2025 Mar 17, 2025 Mar 17, 2025 Mar 3, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Anika Reports Third Quarter 2026 Financial Results Bull 5 Bear 4 Results

Revenue Increased 10% Year Over Year, Led by 17% Commercial Channel Growth Including More Than 30% Growth in IntegrityTM Revenue

Secured New 10-Year Hyvisc® Partnership with Enhanced Economics; Reintroduced Hyaff Non-Orthopedic OEM Product

Raised Lower End of Full-Year 2026 Total Company Revenue Guidance and Raised 2026 Adjusted EBITDA Guidance

Bedford, Mass., November 6, 2026 — Anika Therapeutics, Inc. (Nasdaq: ANIK), the global leader in the design, development, manufacturing and commercialization of hyaluronic acid (HA) innovations, today announced financial results for the third quarter of 2026.

Total revenue for the third quarter was $30.6 million, compared with $27.8 million in the prior-year period, representing 10% year over year growth. Performance was driven by continued Commercial Channel growth and steady Original Equipment Manufacturer (OEM) Channel execution, with Commercial Channel revenue of $14.0 million, up approximately 17% year over year, and OEM Channel revenue of $16.6 million, up approximately 5% year over year.

Third quarter results reflected continued progress on Anika’s strategy to accelerate revenue growth, strengthen operations and advance the pipeline. International viscosupplement revenue increased 19% year over year, total Regenerative Solutions revenue increased 12%, and Integrity revenue grew both sequentially and by more than 30% year over year despite more market-wide seasonality than usual in the summer months. Strong Integrity performance was supported in part by the larger implant sizes introduced in the fourth quarter of 2025 and first quarter of 2026, respectively, which expanded use into other tendon applications including foot & ankle and knee.

“Through the first nine months of 2026, we have executed against the three priorities we established at the start of the year: accelerating revenue growth, strengthening operational execution and advancing our pipeline. We delivered double-digit year to date revenue growth across both channels, secured a long-term agreement that improves the durability and economics of an important commercial relationship, increased manufacturing capacity to support future growth, fully enrolled the Cingal bioequivalence study and expanded Integrity adoption,” said Steve Griffin, President and Chief Executive Officer. “Third quarter results reflect the continued execution against these priorities and represent key milestones to improve durable growth and drive sustained profitability. Taken together, this progress reinforces our confidence in our full-year 2026 outlook and our 2027 revenue expectations.”

Accelerating Revenue Growth
Anika delivered a solid third quarter, highlighted by growth across both channels and continued progress on key pipeline and operational priorities. Through the first nine months, Anika has delivered double-digit revenue growth in both channels, with Commercial Channel revenue increasing 15% and OEM Channel revenue increasing 11% year to date. As part of the Company’s strategy to drive sustainable long-term growth, an enhanced long-term commercial agreement with improved economics has been secured increasing revenue visibility and unlocking additional value in one of our non-orthopedic product franchises.

Strengthening Operational Discipline
Operational discipline remains central to Anika’s value creation strategy. Gross margin improved meaningfully year over year driven by manufacturing productivity offset partially by product mix from the reintroduction of Hyalomatrix®, a Hyaff wound product. Anika continues to improve manufacturing execution through stronger production planning, process improvements and sourcing flexibility, including FDA approval of new aseptic manufacturing processes and validation of a second cross-link filler. Because demand has exceeded forecasts, the Company has significantly increased throughput. Unit volumes on Anika’s cross-link line are now more than 50% above 2022 levels, and further opportunity exists to expand output. As demand continues to grow, the Company is increasing production and building safety stock to support future growth, which is expected to drive additional productivity gains and gross margin improvement over time.

Advancing the Pipeline
In September, enrollment in the Cingal bioequivalence study was completed. Following completion of the clinical study report and chemistry, manufacturing and controls (CMC) work required to file HA as a drug, Anika expects the Cingal new drug application (NDA) to be submitted before year-end 2027.

In October, the Company received formal notification from the FDA that the Hyalofast® pre-market approval (PMA) application is not approvable, primarily based on the clinical data included in the submission. Anika continues to believe strongly in Hyalofast’s potential in the U.S. market and is continuing to assess the available regulatory pathways and next steps, including discussions with the FDA regarding the additional evidence that may be required to support a future approval.

Third Quarter 2026 Business Highlights and Updates

  • Total third quarter revenue was $30.6 million, up 10% year over year, reflecting continued execution across Commercial and OEM Channels.
  • Commercial Channel revenue increased 17% year over year to $14.0 million, supported by international viscosupplement growth and Integrity adoption.
  • International OA Pain Management revenue increased 19% year over year in the third quarter and 16% year to date, reflecting sustained strong demand on both Cingal and Monovisc.
  • OEM Channel revenue increased 5% year over year in the third quarter, supported by Hyvisc growth and J&J DePuy Synthes sales.
  • In November, Anika entered a new 10-year partnership for the distribution of Hyvisc with its existing partner, Boehringer Ingelheim. The agreement provides higher transfer pricing, a royalty on end-market sales, higher contractual purchases and upfront and milestone payments. In total, we expect to receive $8 million in payments, including a $4 million upfront payment in the first quarter of 2027 and remaining $4 million tied to commercial volumes.
  • Integrity revenue recorded sequential growth and increased more than 30% year over year in the third quarter despite a slower than anticipated third quarter elective surgery market. Despite these market dynamics, Integrity contributed $7.5 million in revenue for the trailing 12 months. Strong performance was supported in part by the larger sizes introduced in the fourth quarter of 2025 and first quarter of 2026 which expanded use into other tendon applications including foot & ankle and knee. Integrity revenue has increased 37% year to date. Commercial Channel Revenue 2026 guidance has been updated to reflect this slower elective surgery market.
  • Anika’s second-generation Integrity instrumentation launched in September, providing surgeons with an alternative insertion and deployment option designed to support differences in surgeon preference.
  • In October, Anika received formal notification from the U.S. Food and Drug Administration (FDA) that its Hyalofast PMA application is not approvable, primarily based on the clinical data included in the submission. Anika continues to believe strongly in Hyalofast’s potential in the U.S. market and is assessing available regulatory pathways and next steps.
  • Cingal bioequivalence study enrollment was completed in September, CMC preparation is progressing, and Anika expects an NDA submission before year-end 2027.
  • Anika reintroduced Hyalomatrix, a Hyaff wound product, in the U.S. through a new OEM distributor with first commercial units shipped during the third quarter.

Third Quarter 2026 Continuing Operations Financial Summary

  • Revenue: $30.6 million, up 10% year over year
  • Commercial Channel revenue: $14.0 million, up 17%
  • OEM Channel revenue: $16.6 million, up 5%
  • Gross margin: 62%, compared with 56% in the prior-year period
  • Operating expenses: $19.5 million, up 4% year over year
  • GAAP loss from continuing operations: $0.3 million, or $0.02 per diluted share
  • Adjusted net income from continuing operations¹: $3.9 million, or $0.29 per diluted share
  • Adjusted EBITDA¹: $5.1 million
  • Cash and cash equivalents: $45.0 million as of September 30, 2026

¹See description of non-GAAP financial information contained in this release.

Fiscal 2026 and 2027 Guidance

Anika is raising the lower end of its full-year 2026 total company revenue guidance, reaffirming its full-year 2027 total company revenue guidance and raising full-year 2026 adjusted EBITDA guidance. The Company is updating its 2026 channel revenue guidance to reflect a greater contribution from the OEM Channel and more measured Commercial Channel growth.

2026 Guidance

  • Total Company revenue growth: 6% to 10%, compared to 5% to 10% previously
    • OEM Channel revenue growth: 5% to 9%, compared to 0% to 5% previously
    • Commercial Channel revenue growth: 9% to 13%, compared to 12% to 18% previously
    • Adjusted EBITDA margin: 15% to 17%, compared to 13% to 17% previously

2027 Revenue Guidance

  • Total Company revenue growth: Flat to 5%
    • OEM Channel revenue growth: Flat to modestly lower
    • Commercial Channel revenue growth: 5% to 15%

Conference Call and Webcast Information
Anika’s management will hold a conference call and webcast to discuss its financial results and business highlights on November 6, 2026, at 8:30 am ET. The conference call can be accessed by dialing 1-800-717-1738 (toll-free domestic) or 1-646-307-1865 (international) and providing the conference ID number 27870. A live audio webcast will be available in the Investor Relations section of Anika’s website, www.anika.com . A slide presentation with highlights from the conference call will be available in the Investor Relations section of the Anika website. A replay of the webcast will be available on Anika’s website approximately two hours after the completion of the event.

About Anika
Anika Therapeutics, Inc. (NASDAQ: ANIK), is a global leader in the design, development, manufacturing, and commercialization of hyaluronic acid innovations. In partnership with clinicians, our primary focus is dedicated to delivering and advancing osteoarthritis pain management and orthopedic regenerative solutions. At our core is a passion to deliver a differentiated portfolio that improves patient outcomes around the world. Anika’s global operations are headquartered outside of Boston, Massachusetts. For more information about Anika, please visit www.anika.com .

ANIKA, ANIKA THERAPEUTICS, CINGAL, HYALOFAST, INTEGRITY, MONOVISC, HYVISC, HYALOMATRIX, and the Anika logo are trademarks of Anika Therapeutics, Inc. or its subsidiaries or are licensed to Anika Therapeutics, Inc. for its use.

Non-GAAP Financial Information1
Non-GAAP financial measures should be considered supplemental to, and not a substitute for, Anika’s reported financial results prepared in accordance with GAAP. Furthermore, Anika’s definition of non-GAAP measures may differ from similarly titled measures used by others. Because non-GAAP financial measures exclude the effect of items that will increase or decrease Anika’s reported results of operations, Anika strongly encourages investors to review Anika’s consolidated financial statements and publicly filed reports in their entirety. Anika presents these non-GAAP financial measures because it uses them as supplemental measures in internally assessing its operating performance, and, in the case of Adjusted EBITDA, it is set as a key performance metric to determine executive compensation. Anika also recognizes that these non-GAAP measures are commonly used in determining business performance more broadly and believes that they are helpful to investors, securities analysts, and other interested parties as a measure of comparative operating performance from period to period.

Adjusted EBITDA

Adjusted EBITDA is defined by Anika as GAAP net loss from continuing operations excluding depreciation and amortization, interest and other income (expense), net, income taxes, stock-based compensation expense, non-recurring professional fees and severance costs.

Adjusted Net Income (Loss) from Continuing Operations and Adjusted Earnings Per Share (“EPS”) from Continuing Operations

Adjusted net income (loss) from continuing operations is defined by Anika as GAAP net income (loss) from continuing operations, on a tax effected basis, excluding stock-based compensation, non-recurring professional fees and severance costs. Adjusted diluted EPS from continuing operations is defined by Anika as GAAP diluted EPS from continuing operations excluding stock-based compensation, non-recurring professional fees and severance costs, each on a tax effected and per share basis.

A reconciliation of adjusted EBITDA to adjusted net income (loss) from continuing operations to net income (loss) from continuing operations and adjusted diluted EPS from continuing operations to diluted EPS from continuing operations, the most directly comparable financial measures calculated and presented in accordance with GAAP, is shown in the tables at the end of this release.

Anika has not provided a reconciliation of its forward-looking adjusted EBITDA margin guidance to the most directly comparable GAAP financial measure because it is unable to predict with reasonable certainty the occurrence or amount of items such as stock-based compensation expense, severance costs, non-recurring professional fees and certain other items that may affect GAAP results. The effect of these items could be material, and therefore a reconciliation is not available without unreasonable effort.

Forward-Looking Statements
This press release may contain forward-looking statements, within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, concerning Anika’s expectations, anticipations, intentions, beliefs or strategies regarding the future which are not statements of historical fact, including express or implied statements regarding Anika’s 2026 revenue and adjusted EBITDA guidance, and 2027 revenue guidance; Anika’s product development activities, including clinical trials, regulatory submissions and reviews, including for Cingal and Hyalofast;, manufacturing improvements and capacity expansion; receipt of milestone payments and royalties; margin contributions from product reintroductions; and other, operational initiatives and pipeline advancement, among others. These express or implied statements are based upon the current beliefs and expectations of Anika’s management and are subject to significant risks, uncertainties, and other factors. Anika's actual results could differ materially from any anticipated future results, performance, or achievements described in the forward-looking statements as a result of a number of factors including, but not limited to, risks related to (i) Anika’s ability to successfully commence and/or complete clinical trials of its products on a timely basis or at all; (ii) Anika’s ability to obtain pre-clinical or clinical data to support regulatory approvals; (iii) other regulatory, commercial, and operational risks, including related to manufacturing, production planning, addressing customer demands and supply chain risks ; (iv)achieving success from its research and product development efforts, including any future product sales; (v) the cost effectiveness and efficiency of its manufacturing operations and production planning; (vi) the strength of the economies in which Anika operates or will be operating, as well as political stability in such geographies; (vii) future resource allocation determinations; (viii) achieving growth targets and realizing expected economic benefits; (ix) receipt of milestone payments and royalties under its distribution agreements, including the recently renewed Boehringer Ingelheim agreement; and (x) achieving anticipated margin contributions and commercial returns from product reintroductions and new product launches. Additional factors and risks are described in Anika’s periodic reports filed with the Securities and Exchange Commission, and they are available on the SEC's website at www.sec.gov. Forward-looking statements are made based on information available on the date of this press release, and Anika assumes no obligation to update the information contained in this press release.

For Investor Inquiries:
Anika Therapeutics, Inc.

Matt Hall, 781-457-9554
Executive Director, Corporate Development and Investor Relations
[email protected]

Anika Therapeutics, Inc. and Subsidiaries
Consolidated Statements of Operations
(in thousands, except per share data)
(unaudited)
For the Three Months Ended September 30, For the Nine Months Ended September 30,
2026 2025 2026 2025
Revenue $ 30,594 $ 27,817 $ 92,816 $ 82,204
Cost of revenue 11,757 12,233 33,738 37,576
Gross profit 18,837 15,584 59,078 44,628
Operating expenses:
Research and development 7,895 6,946 21,949 19,318
Selling, general and administrative 11,654 11,871 40,375 37,007
Total operating expenses 19,549 18,817 62,324 56,325
Loss from operations (712) (3,233) (3,246) (11,697)
Interest and other income (expense), net 390 997 1,483 1,626
Loss before income taxes (322) (2,236) (1,763) (10,071)
(Benefit from) provision for income taxes (11) 939 295 1,709
Loss from continuing operations (311) (3,175) (2,058) (11,780)
Income from discontinued operations, net of tax - 846 - 608
Net loss $ (311) $ (2,329) $ (2,058) $ (11,172)
Net income (loss) per share:
Basic
Continuing Operations $ (0.02) $ (0.22) $ (0.15) $ (0.82)
Discontinued Operations $ - $ 0.06 $ - $ 0.04
$ (0.02) $ (0.16) $ (0.15) $ (0.78)
Diluted
Continuing Operations $ (0.02) $ (0.22) $ (0.15) $ (0.82)
Discontinued Operations $ - $ 0.06 $ - $ 0.04
$ (0.02) $ (0.16) $ (0.15) $ (0.78)
Weighted average common shares outstanding:
Basic 13,388 14,419 13,416 14,361
Diluted 13,388 14,419 13,416 14,361
Anika Therapeutics, Inc. and Subsidiaries
Consolidated Balance Sheets
(in thousands, except per share data)
(unaudited)
September 30, December 31,
ASSETS 2026 2025
Current assets:
Cash and cash equivalents $ 44,957 $ 57,481
Accounts receivable, net 24,255 23,690
Inventories, net 30,351 18,787
Prepaid expenses and other current assets 3,482 3,400
Total current assets 103,045 103,358
Property and equipment, net 40,739 40,324
Right-of-use assets 25,775 25,939
Other long-term assets 3,931 4,034
Notes receivable 5,754 5,636
Deferred tax assets 925 1,275
Intangible assets, net 1,650 1,650
Goodwill 7,781 8,054
Total assets $ 189,600 $ 190,270
LIABILITIES AND STOCKHOLDERS� EQUITY
Current liabilities:
Accounts payable $ 6,033 $ 6,041
Accrued expenses and other current liabilities 20,692 15,867
Total current liabilities 26,725 21,908
Other long-term liabilities 733 701
Lease liabilities 24,565 24,196
Stockholders� equity:
Common stock, $0.01 par value 134 139
Additional paid-in-capital 84,131 87,498
Accumulated other comprehensive loss (5,417) (4,959)
Retained earnings 58,729 60,787
Total stockholders equity 137,577 143,465
Total liabilities and stockholders equity $ 189,600 $ 190,270
Anika Therapeutics, Inc. and Subsidiaries
Consolidated Statements of Cash Flows
(in thousands)
(unaudited)
For the Nine Months Ended September 30,
2026 2025
Cash flows from operating activities:
Net loss $ (2,058) $ (11,172)
Adjustments to reconcile net loss to net cash provided by operating activities:
Depreciation 4,351 4,054
Amortization of acquisition related intangible assets - 357
Non-cash operating lease cost 1,390 1,562
Stock-based compensation expense 12,718 7,626
Deferred income taxes 329 18
Provision for doubtful accounts (57) 209
Provision for inventory 3,190 4,969
Interest income on notes receivable (384) (424)
Loss (gain) on sale of assets 6 (956)
Changes in operating assets and liabilities:
Accounts receivable (645) 1,953
Inventories (14,327) 1,809
Prepaid expenses, other current and long-term assets (1,386) 1,016
Accounts payable (455) (835)
Operating lease liabilities (1,324) (1,525)
Accrued expenses, other current and long-term liabilities 541 (1,641)
Income taxes 958 (469)
Net cash provided by operating activities 2,847 6,551
Cash flows from investing activities:
Proceeds from sale of Parcus - 4,496
Proceeds from sale of intangible assets - 600
Notes receivable 266 483
Purchases of property and equipment (4,541) (6,178)
Net cash used in investing activities (4,275) (599)
Cash flows from financing activities:
Proceeds from employee stock purchase plan 198 261
Cash paid for tax withheld on vested restricted stock awards (1,742) (1,562)
Proceeds from exercises of equity awards 12 -
Repurchases of common stock (9,543) (3,971)
Net cash used in financing activities (11,075) (5,272)
Exchange rate impact on cash (21) 151
(Decrease) increase in cash and cash equivalents (12,524) 831
Cash and cash equivalents at beginning of period 57,481 57,159
Cash and cash equivalents at end of period $ 44,957 $ 57,990

 

Anika Therapeutics, Inc. and Subsidiaries
Reconciliation of GAAP Income (Loss) from Continued Operations to Adjusted EBITDA
(in thousands)
(unaudited)
For the Three Months Ended September 30, For the Nine Months Ended September 30,
2026 2025 2026 2025
Loss from continuing operations $ (311) $ (3,175) $ (2,058) $ (11,780)
Interest and other (income) expense, net (390) (997) (1,483) (1,626)
Provision for income taxes (11) 939 295 1,709
Depreciation and amortization 1,439 1,403 4,351 4,263
Stock-based compensation 4,244 2,215 12,718 7,758
Non-recurring professional fees - 480 169 480
Severance costs 127 - 2,486 -
Adjusted EBITDA $ 5,098 $ 865 $ 16,478 $ 804
Anika Therapeutics, Inc. and Subsidiaries
Reconciliation of GAAP Net Income from Continuing Operations to Adjusted Net Income from Continuing Operations
(in thousands)
(unaudited)
For the Three Months Ended September 30, For the Nine Months Ended September 30,
2026 2025 2026 2025
Loss from continuing operations $ (311) $ (3,175) $ (2,058) $ (11,780)
Stock-based compensation, tax effected 4,099 3,145 14,846 9,075
Non-recurring professional fees, tax effected - 682 197 561
Severance costs, tax effected 123 - 2,902 -
Adjusted net income (loss) from continuing operations $ 3,911 $ 652 $ 15,887 $ (2,144)
Anika Therapeutics, Inc. and Subsidiaries
Reconciliation of GAAP Diluted Earnings from Continuing Operations Per Share to Adjusted Diluted Earnings from Continuing Opertions Per Share
(in thousands, except per share data)
(unaudited)
For the Three Months Ended September 30, For the Nine Months Ended September 30,
2026 2025 2026 2025
Diluted loss from continuing operations per share $ (0.02) $ (0.22) $ (0.15) $ (0.82)
Stock-based compensation, tax effected 0.30 0.21 1.11 0.63
Non-recurring professional fees, tax effected - 0.05 - 0.04
Severance costs, tax effected 0.01 - 0.22 -
Adjusted diluted income (loss) from continuing operations per share $ 0.29 $ 0.04 $ 1.18 $ (0.15)

 

Anika Therapeutics, Inc. and Subsidiaries
Revenue by Channel
(in thousands, except percentages)
(unaudited)
For the Three Months Ended September 30, For the Nine Months Ended September 30,
2026 2025 $ change % change 2026 2025 $ change % change
OEM Channel $ 16,601 $ 15,844 $ 757 5 % $ 52,341 $ 47,093 $ 5,248 11 %
Commercial Channel 13,993 11,973 2,020 17 % 40,475 35,111 5,364 15 %
$ 30,594 $ 27,817 $ 2,777 10 % $ 92,816 $ 82,204 $ 10,612 13 %

Anika Therapeutics

Financials & Stock

News & Governance

Resources

Follow Us

© 2026 Anika Therapeutics. All rights reserved.

Privacy Policy Terms of Use

To Top

(opens in a new window)

BEDFORD, Mass., October 22, 2026 -- Anika Therapeutics, Inc.

(NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, announced today that it will issue its third quarter 2026 financial results before the opening of the market on Friday, November 6, 2026, followed by a conference call at 8:30 a.m. ET to discuss its results and business highlights.

The conference call can be accessed by dialing 1-800-717-1738 (toll-free domestic) or 1-646-307-1865 (international) and providing the conference ID number 27870. A live audio webcast and accompanying presentation materials will be available in the Investor Relations

section of Anika's website, www.anika.com

. The call will be archived and accessible on the same website shortly after its conclusion.

Anika Reports Second Quarter 2026 Financial Results Bull 5 Bear 0 Results

Commercial Channel Revenue Increased 17% to a Record $13.9 Million

Delivered $3.3 Million of Net Income, 65% Gross Margin, and $7.1 Million of Adjusted EBITDA, Highest Since 2020

Raising Full-Year 2026 Financial Guidance and Revising 2027 Revenue Forecast

BEDFORD, Mass., July 28, 2026 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (Nasdaq: ANIK), a global leader in the osteoarthritis ("OA") pain management and regenerative solutions spaces focused on early-intervention orthopedics, today announced financial results for the second quarter of 2026.

Total revenue for the second quarter was $32.6 million, compared to $28.2 million in the prior-year period. Performance was driven by record Commercial Channel revenue of $13.9 million**,** representing organic growth of 17% year-over-year**,** and continued strength in the OEM Channel supported by favorable US Monovisc and Orthovisc sales.

Gross profit for the second quarter was $21.2 million**,** compared to $14.4 million in the prior-year period. Gross margin expanded to 65%, reflecting higher sales volume, increased manufacturing production and improved sales mix.

Total operating expenses were $18.3 million, compared to $18.5 million in the prior-year period. Operating expense performance reflected continued cost discipline across the business while maintaining targeted investments to support commercial growth and strategic development programs. Excluding approximately $0.8 million of one-time severance-related expenses, adjusted operating expenses were $17.5 million, representing a decline of 6% versus the prior-year period.

Net income was $3.3 million for the second quarter, representing a 10% margin. Adjusted EBITDA was $7.1 million, representing a 22% Adjusted EBITDA margin reflecting continued benefits from commercial growth, gross margin expansion, and disciplined expense management.

"Our second quarter results mark a positive step forward in improving the performance of our business. We achieved record Commercial Channel revenue, substantial gross margin expansion, and our highest adjusted EBITDA since 2020. The actions we initiated earlier this year are delivering early gains as we continue to drive operational excellence throughout the Company. Additionally, our growth has diversified across channels and geographies, highlighted by a record quarter of international revenue.” said Steve Griffin, President and Chief Executive Officer.

“Our OEM business continues to perform well, supported by stronger transfer unit volumes driven by J&J DePuy Synthes, order timing across both the Monovisc and Orthovisc product lines, favorable U.S. Monovisc end market sales, and continued international growth. These drivers increased production, throughput and manufacturing yields, resulting in meaningful gross margin expansion and operating leverage. Combined with disciplined expense management, a 20% reduction in G&A expenses (or 30% excluding one-time severance-related charges), and lower stock-based compensation expense, these improvements are translating into meaningful profitability gains.

Given our first-half performance, we are raising our full-year financial outlook. Most notably, we are raising our adjusted EBITDA margin outlook to 13%-17%, driven by improved operating leverage. Our improved outlook is supported by favorable OEM sales trends, continued Commercial Channel growth, operational improvements, and disciplined cost management. While we expect some moderation in revenue and profitability during the second half relative to the strong first half, reflecting the timing of certain OEM orders, we remain encouraged by the underlying trends in the business and our ability to deliver improved full-year performance. We are still early in our company-wide transformation, yet the results achieved in the first half reinforce that our strategy is working and that disciplined execution against our mission is creating sustainable value.

As we continue to advance toward filing the Cingal New Drug Application (“NDA”) we’re making steady progress on the bioequivalence study for Triamcinolone Hexacetonide and are accelerating the necessary Chemistry, Manufacturing and Controls (“CMC”), activities required to file Cingal as a drug-drug combination product. Additionally, we remain actively engaged with the U.S. Food and Drug Administration (“FDA”) on Hyalofast, with discussions focusing primarily on the co-primary clinical endpoints within the Premarket Approval (“PMA”) submission.

Given the timing uncertainty that remains in our regulatory review process, particularly as our discussions with the FDA on Hyalofast evolve, we are adopting a new revenue guidance practice. Going forward, our forecast will only include revenue from products that have received regulatory approval or clearance. As a result, our 2027 Commercial Channel revenue guidance no longer includes revenue associated with Hyalofast.”

Second Quarter 2026 Business Highlights and Updates

  • Strong first-half execution drove record revenue performance, significant gross margin expansion, and a raise to full-year revenue and EBITDA guidance.
  • Commercial Channel revenue increased 17% year-over-year to a record $13.9 million, representing the strongest quarter in Company history. 
  • International revenue reached a record $12.6 million, increasing 22% year-over-year and exceeding the prior quarterly record by 5%, reflecting continued strength across key markets and the increasing contribution from Anika's global commercial organization.
  • OEM Channel performance benefited from strong transfer units, favorable order timing and Monovisc volume growth, partially offset by lower Orthovisc sales.
  • Integrity global units increased both sequentially and year-over-year during the second quarter, driven by growing international demand and continued adoption of larger implant shapes and sizes in the US. Year-to-date sales grew 39% year over year.
  • Hyalofast PMA activities continue to advance, with the Company remaining actively engaged with the FDA as it works through the ongoing review process and responses to the previously disclosed deficiency letter.
  • Cingal development remains on track, with bioequivalence study enrollment progressing as planned. Concurrently, the required CMC activities supporting hyaluronic acid as a drug are accelerating in preparation for the NDA submission.

Second Quarter 2026 Continuing Operations Financial Summary

  • Revenue: $32.6 million, up 16% year over year
  • Commercial Channel revenue: $13.9 million, up 17%
  • OEM Channel revenue: $18.7 million, up 14%
  • Gross margin: 65%
  • Operating expenses: $18.3 million
  • GAAP income (loss) from continuing operations: $3.3 million**,** $0.24 per diluted share
  • Adjusted net income from continuing operations¹: $5.9 million**,** $0.42 per diluted share
  • Adjusted EBITDA¹: $7.1 million
  • Cash and cash equivalents: $38.4 million as of June 30, 2026

¹See description of non-GAAP financial information contained in this release.

Fiscal 2026 Guidance

Based on strong first-half operating performance, continued commercial momentum, favorable OEM dynamics, and improved profitability, Anika is raising its full-year 2026 guidance.

Updated 2026 Guidance

  • Raising Total Company Revenue Guidance: revenue growth of 5% to 10%, compared to previous guidance of 1% to 9%
    • OEM Channel revenue growth: 0% to 5%, compared to previous guidance of down 5% to flat
    • Commercial Channel revenue growth: 12% to 18%, compared to previous guidance of 10% to 20%
  • Adjusted EBITDA margin: 13% to 17%, compared to previous guidance of 5% to 10%

Updated 2027 Revenue Guidance

Anika has adopted a new revenue guidance practice. Going forward, the Company’s forecast will only include revenue for products that have received regulatory approval or clearance.

  • 2027 Commercial Channel revenue growth: 5% to 15%, compared to previous guidance of 10% to 20%
  • 2027 OEM revenue growth: Unchanged, flat to modestly lower
  • 2027 Total Company revenue: flat to 5% growth

Conference Call and Webcast Information
Anika’s management will hold a conference call and webcast to discuss its financial results and business highlights today, Wednesday, July 29, 2026, at 8:30 am ET. The conference call can be accessed by dialing 1-800-717-1738 (toll-free domestic) or 1-646-307-1865 (international) and providing the conference ID number 60388. A live audio webcast will be available in the Investor Relations section of Anika’s website, www.anika.com . A slide presentation with highlights from the conference call will be available in the Investor Relations section of the Anika website. A replay of the webcast will be available on Anika’s website approximately two hours after the completion of the event.

About Anika
Anika Therapeutics, Inc. (NASDAQ: ANIK), is the global leader in the design, development, manufacturing, and commercialization of hyaluronic acid innovations. In partnership with clinicians, our sole focus is dedicated to delivering and advancing osteoarthritis pain management and orthopedic regenerative solutions. At our core is a passion to deliver a differentiated portfolio that improves patient outcomes around the world. Anika’s global operations are headquartered outside of Boston, Massachusetts. For more information about Anika, please visit www.anika.com .

ANIKA, ANIKA THERAPEUTICS, CINGAL, HYALOFAST, INTEGRITY, MONOVISC, and the Anika logo are trademarks of Anika Therapeutics, Inc. or its subsidiaries or are licensed to Anika Therapeutics, Inc. for its use.

Non-GAAP Financial Information****1
Non-GAAP financial measures should be considered supplemental to, and not a substitute for, the Company’s reported financial results prepared in accordance with GAAP. Furthermore, the Company’s definition of non-GAAP measures may differ from similarly titled measures used by others. Because non-GAAP financial measures exclude the effect of items that will increase or decrease the Company’s reported results of operations, Anika strongly encourages investors to review the Company’s consolidated financial statements and publicly filed reports in their entirety. The Company presents these non-GAAP financial measures because it uses them as supplemental measures in internally assessing the Company’s operating performance, and, in the case of Adjusted EBITDA, it is set as a key performance metric to determine executive compensation. The Company also recognizes that these non-GAAP measures are commonly used in determining business performance more broadly and believes that they are helpful to investors, securities analysts, and other interested parties as a measure of comparative operating performance from period to period.

Adjusted EBITDA
Adjusted EBITDA is defined by the Company as GAAP net income (loss) from continuing operations excluding depreciation and amortization, interest and other income (expense), income taxes, stock-based compensation expense, and non-recurring professional fees and severance costs.

Adjusted Net Income (Loss) from Continuing Operations and Adjusted Earnings Per Share (“EPS”) from Continuing Operations
Adjusted net income (loss) is defined by the Company as GAAP net income (loss) from continuing operations, on a tax effected basis, excluding stock-based compensation, severance costs and non-recurring professional fees. Adjusted diluted EPS from continuing operations is defined by the Company as GAAP diluted EPS from continuing operations excluding stock-based compensation, severance costs and non-recurring professional fees, each on a tax effected basis.

A reconciliation of adjusted EBITDA to adjusted net income (loss) from continuing operations to net income (loss) from continuing operations and adjusted diluted EPS from continuing operations to diluted EPS from continuing operations, the most directly comparable financial measures calculated and presented in accordance with GAAP, is shown in the tables at the end of this release.

The Company has not provided a reconciliation of its forward-looking adjusted EBITDA margin guidance to the most directly comparable GAAP financial measure because it is unable to predict with reasonable certainty the occurrence or amount of items such as stock-based compensation expense, severance costs, non-recurring professional fees and certain other items that may affect GAAP results. The effect of these items could be material, and therefore a reconciliation is not available without unreasonable effort.

Forward-Looking Statements
This press release may contain forward-looking statements, within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, concerning the Company's expectations, anticipations, intentions, beliefs or strategies regarding the future which are not statements of historical fact, including statements in the sections titled “Fiscal 2026 Guidance” and “Updated 2027 Revenue Guidance” regarding 2026 and 2027 revenue, adjusted EBITDA and related financial outlook_. These statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks, uncertainties, and other factors. The Company's actual results could differ materially from any anticipated future results, performance, or achievements described in the forward-looking statements as a result of a number of factors including, but not limited to, (i) the Company's ability to successfully commence and/or complete clinical trials of its products on a timely basis or at all; (ii) the Company's ability to obtain pre-clinical or clinical data to support, or to timely file domestic and international pre-market approval applications, 510(k) applications, or new drug applications, including the PMA for Hyalofast and the NDA for Cingal; (iii) that the FDA or other regulatory bodies may not approve or clear the Company’s applications, including the Hyalofast PMA because of the failure to achieve the pre-defined primary endpoints or because the FDA may determine that achievement of secondary endpoints and/or post hoc data analyses are not sufficient to support approval; (iv) that such approvals or clearances will not be obtained in a timely manner or without the need for additional clinical trials, other testing or regulatory submissions, as applicable; (v) the Company's research and product development efforts and their relative success, including whether the Company has any meaningful sales of any new products resulting from such efforts; (vi) the cost effectiveness and efficiency of the Company's clinical studies, manufacturing operations, and production planning; (vii) the strength of the economies in which the Company operates or will be operating, as well as the political stability of any of those geographic areas; (viii) future determinations by the Company to allocate resources to products and in directions not presently contemplated; (ix) the Company's ability to successfully commercialize its products, in the U.S. and abroad; (x) the Company's ability to provide an adequate and timely supply of its products to its customers; (xi) the Company's ability to achieve its growth targets; and (xii) the Company's ability to realize anticipated cost savings, operational efficiencies and other benefits from its restructuring actions and strategic transformation initiatives. Additional factors and risks are described in the Company's periodic reports filed with the Securities and Exchange Commission, and they are available on the SEC's website at_ www.sec.gov . Forward-looking statements are made based on information available to the Company on the date of this press release, and the Company assumes no obligation to update the information contained in this press release.

For Investor Inquiries:
Anika Therapeutics, Inc.
Matt Hall, 781-457-9554
Executive Director, Corporate Development and Investor Relations
[email protected]

Anika Therapeutics, Inc. and Subsidiaries
Consolidated Statements of Operations
(in thousands, except per share data)
(unaudited)
For the Three Months Ended June 30, For the Six Months Ended June 30,
2026 2025 2026 2025
Revenue $ 32,610 $ 28,219 $ 62,222 $ 54,387
Cost of Revenue 11,366 13,856 21,981 25,343
Gross Profit 21,244 14,363 40,241 29,044
Operating expenses:
Research and development 7,341 6,313 14,054 12,372
Selling, general and administrative 10,949 12,230 28,721 25,136
Total operating expenses 18,290 18,543 42,775 37,508
Income (loss) from operations 2,954 (4,180) (2,534) (8,464)
Interest and other income (expense), net 426 214 1,093 629
Income (loss) before income taxes 3,380 (3,966) (1,441) (7,835)
Provision for income taxes 71 681 306 770
Income (loss) from continuing operations 3,309 (4,647) (1,747) (8,605)
Income (loss) from discontinued operations, net of tax - 677 - (238)
Net income (loss) $ 3,309 $ (3,970) $ (1,747) $ (8,843)
Net income (loss) per share:
Basic
Continuing Operations $ 0.25 $ (0.33) $ (0.13) $ (0.60)
Discontinued Operations $ - $ 0.05 $ - $ (0.02)
$ 0.25 $ (0.28) $ (0.13) $ (0.62)
Diluted
Continuing Operations $ 0.24 $ (0.33) $ (0.13) $ (0.60)
Discontinued Operations $ - $ 0.05 $ - $ (0.02)
$ 0.24 $ (0.28) $ (0.13) $ (0.62)
Weighted average common shares outstanding:
Basic 13,330 14,364 13,430 14,331
Diluted 13,717 14,517 13,430 14,331
Anika Therapeutics, Inc. and Subsidiaries
Consolidated Balance Sheets
(in thousands, except per share data)
(unaudited)
June 30, December 31,
ASSETS 2026 2025
Current assets:
Cash and cash equivalents $ 38,412 $ 57,481
Accounts receivable, net 29,062 23,690
Inventories, net 28,565 18,787
Prepaid expenses and other current assets 3,151 3,400
Total current assets 99,190 103,358
Property and equipment, net 40,102 40,324
Right-of-use assets 24,949 25,939
Other long-term assets 3,023 4,034
Notes receivable 5,718 5,636
Deferred tax assets 1,017 1,275
Intangible assets, net 1,650 1,650
Goodwill 7,825 8,054
Total assets $ 183,474 $ 190,270
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable $ 6,236 $ 6,041
Accrued expenses and other current liabilities 15,911 15,867
Total current liabilities 22,147 21,908
Other long-term liabilities 730 701
Lease liabilities 23,315 24,196
Stockholders’ equity:
Common stock, $0.01 par value 134 139
Additional paid-in-capital 83,437 87,498
Accumulated other comprehensive loss (5,329) (4,959)
Retained earnings 59,040 60,787
Total stockholders’ equity 137,282 143,465
Total liabilities and stockholders’ equity $ 183,474 $ 190,270
Anika Therapeutics, Inc. and Subsidiaries
Consolidated Statements of Cash Flows
(in thousands)
(unaudited)
For the Six Months Ended June 30,
2026 2025
Cash flows from operating activities:
Net loss $ (1,747) $ (8,843)
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation 2,912 2,663
Amortization of acquisition related intangible assets - 345
Non-cash operating lease cost 929 1,067
Stock-based compensation expense 8,474 5,411
Deferred income taxes 237 15
Provision for doubtful accounts (97) 133
Provision for inventory 2,575 3,842
Interest income on notes receivable (354) (345)
Gain on sale of assets (84) (505)
Changes in operating assets and liabilities:
Accounts receivable (5,408) 659
Inventories (11,420) 2,252
Prepaid expenses, other current and long-term assets (831) 797
Accounts payable 170 (1,066)
Operating lease liabilities (937) (1,045)
Accrued expenses, other current and long-term liabilities (1,074) (5,251)
Income taxes 1,125 (448)
Net cash provided by operating activities (5,530) (319)
Cash flows from investing activities:
Proceeds from sale of Parcus - 4,496
Proceeds from sale of intangible assets - 600
Notes receivable 361 328
Purchases of property and equipment (2,880) (4,291)
Net cash used in investing activities (2,519) 1,133
Cash flows from financing activities:
Proceeds from employee stock purchase plan 198 261
Cash paid for tax withheld on vested restricted stock awards (1,715) (1,549)
Proceeds from exercises of equity awards 12 -
Repurchases of common stock (9,543) (3,971)
Net cash used in financing activities (11,048) (5,259)
Exchange rate impact on cash 28 453
Increase (decrease) in cash and cash equivalents (19,069) (3,992)
Cash and cash equivalents at beginning of period 57,481 57,159
Cash and cash equivalents at end of period $ 38,412 $ 53,167

 

Anika Therapeutics, Inc. and Subsidiaries
Reconciliation of GAAP Income (Loss) from Continued Operations to Adjusted EBITDA
(in thousands)
(unaudited)
For the Three Months Ended June 30, For the Six Months Ended June 30,
2026 2025 2026 2025
Income (loss) from continuing operations $ 3,309 $ (4,647) $ (1,747) $ (8,605)
Interest and other (income) expense, net (426) (214) (1,093) (629)
Provision for income taxes 71 681 306 770
Depreciation and amortization 1,505 1,444 2,912 2,860
Stock-based compensation 1,833 2,548 8,474 5,543
Non-recurring professional fees - - 169 -
Severance costs 772 - 2,359 -
Adjusted EBITDA $ 7,064 $ (188) $ 11,380 $ (61)
Anika Therapeutics, Inc. and Subsidiaries
Reconciliation of GAAP Net Income from Continuing Operations to Adjusted Net Income from Continuing Operations
(in thousands)
(unaudited)
For the Three Months Ended June 30, For the Six Months Ended June 30,
2026 2025 2026 2025
Income (loss) from continuing operations $ 3,309 $ (4,647) $ (1,747) $ (8,605)
Stock-based compensation, tax effected 1,794 2,986 10,274 6,088
Non-recurring professional fees, tax effected - - 205 -
Severance costs, tax effected 756 - 2,860 -
Adjusted net income (loss) from continuing operations $ 5,859 $ (1,661) $ 11,592 $ (2,517)
Anika Therapeutics, Inc. and Subsidiaries
Reconciliation of GAAP Diluted Earnings from Continuing Operations Per Share to Adjusted Diluted Earnings from Continuing Opertions Per Share
(in thousands, except per share data)
(unaudited)
For the Three Months Ended June 30, For the Six Months Ended June 30,
2026 2025 2026 2025
Diluted income (loss) from continuing operations per share $ 0.24 $ (0.33) $ (0.13) $ (0.60)
Stock-based compensation, tax effected 0.13 0.20 0.76 0.43
Non-recurring professional fees, tax effected - 0.02 -
Severance costs, tax effected 0.05 - 0.21 -
Adjusted diluted income (loss) from continuing operations per share $ 0.42 $ (0.13) $ 0.86 $ (0.17)
Anika Therapeutics, Inc. and Subsidiaries
Revenue by Product Family
(in thousands, except percentages)
(unaudited)
For the Three Months Ended June 30, For the Six Months Ended June 30,
2026 2025 $ change % change 2026 2025 $ change % change
OEM Channel $ 18,705 $ 16,340 $ 2,365 14 % $ 35,740 $ 31,249 $ 4,491 14 %
Commercial Channel 13,905 11,879 2,026 17 % 26,482 23,138 3,344 14 %
$ 32,610 $ 28,219 $ 4,391 16 % $ 62,222 $ 54,387 $ 7,835 14 %

Anika Therapeutics

Financials & Stock

News & Governance

Resources

Follow Us

© 2026 Anika Therapeutics. All rights reserved.

Privacy Policy Terms of Use

To Top

(opens in a new window)

Prompts

Anika Therapeutics Inc. (ticker ANIK), listed in United States.

ETFs Holding Anika Therapeutics Inc.

ETF Weight in ETF Shares Market value As of
SQLV 0.19% 3,649 $ 53.385K Jun 30, 2026
FSEV 0.05% 250 $ 3,657.50 Jun 30, 2026
FEAC 0.04% 778 $ 11.382K Jun 30, 2026
AVSC 0.01% 25,985 $ 335.726K Nov 16, 2026
DFSV 0.01% 156,005 $ 2.154M Nov 12, 2026
DFAS 0.00% 99,534 $ 1.375M Nov 12, 2026
DXUV 0.00% 12,694 $ 175.304K Nov 12, 2026
DFAT 0.00% 31,556 $ 435.788K Nov 12, 2026
DFSU 0.00% 1,000 $ 13.81K Nov 12, 2026
DFUV 0.00% 6,027 $ 83.233K Nov 12, 2026
DCOR 0.00% 12,088 $ 166.935K Nov 12, 2026
DFAU 0.00% 3,440 $ 47.506K Nov 12, 2026
DFAC 0.00% 14,692 $ 202.897K Nov 12, 2026
DFUS 0.00% 1,888 $ 26.073K Nov 12, 2026
AVUS 0.00% 3,415 $ 44.122K Nov 16, 2026
AVSU 0.00% 385 $ 4,974.20 Nov 16, 2026